Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  American Journal of Psychiatry

• Publication date

  2011-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1176/appi.ajp.2010.09010087PMID 21205805PMCID PMC5069345
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Individual placement and support for individuals with recent-onset schizophrenia: integrating supported education and supported employment.

  2008cited by this paper
• Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting.

  2008cited by this paper
• One year outcome in first episode schizophrenia. Predictors of relapse.

  2006cited by this paper
• Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial

  2006cited by this paper
• Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia

  2006cited by this paper
• Classifying episodes in schizophrenia and bipolar disorder: criteria for relapse and remission applied to recent-onset samples.

  2006cited by this paper
• Defining and assessing adherence to oral antipsychotics: a review of the literature.

  2005influential reference
• A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients.

  2005cited by this paper
• Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia.

  2004cited by this paper
• Supplementing supported employment with workplace skills training.

  2004cited by this paper
• Rehab Rounds: Supplementing Supported Employment With Workplace Skills Training

  2004cited by this paper
• A Working Life for People With Severe Mental Illness

  2004cited by this paper
• Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors.

  2004cited by this paper
• Factors influencing compliance in schizophrenia patients.

  2003cited by this paper
• Adherence to antipsychotic medication

  2002cited by this paper
• Using drug claims data to assess the relationship of medication adherence with hospitalization and costs.

  2001cited by this paper
• Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis

  2001cited by this paper
• Psychopharmacology: insight and comorbid substance misuse and medication compliance among patients with schizophrenia.

  2001cited by this paper
• Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.

  1999cited by this paper
• Adherence to antipsychotic medications.

  1999cited by this paper
• Electrodermal activity as a prodromal sign in schizophrenia.

  1997cited by this paper
• Structured Clinical Interview for DSM-IV Axis I Disorders

  1997influential reference
• Awareness of Illness in Schizophrenia and Outpatient Treatment Adherence

  1996cited by this paper
• Neuropsychological prediction of treatment efficacy and one-year outcome in schizophrenia.

  1993cited by this paper
• Brief Psychiatric Rating Scale (BPRS) Expanded Version (4.0): Scales, Anchor Points, and Administration Manual

  1993influential reference
• Neuroleptic noncompliance in schizophrenia

  1989cited by this paper
• Expressed emotion, affective style, lithium compliance, and relapse in recent onset mania.

  1986cited by this paper
• Differences in the Nature of Relapse and Subsequent Inpatient Course between Medication‐Compliant and Noncompliant Schizophrenic Patients

  1984cited by this paper
• Research diagnostic criteria: rationale and reliability.

  1978influential reference
• Major psychiatric disorders. A four-dimensional model.

  1967cited by this paper

• Positive symptoms and medication adherence in response to oral versus long-acting injectable risperidone in black, latino, and white first-episode psychosis patients.

  2025cites this paper
• Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia

  2025cites this paper
• Proxy consultations for severe mental illnesses: An exploratory cross-sectional study from a tertiary care hospital

  2024cites this paper
• Treatment adherence rates across different psychiatric disorders and settings: findings from a large patient cohort

  2024cites this paper
• Effects of Social Support on Medication Adherence Among Patients with Schizophrenia: Serial Multiple Mediation Model

  2024cites this paper
• Effect of treatment with paliperidone palmitate versus oral antipsychotics on frontal lobe intracortical myelin volume in participants with recent-onset schizophrenia: Magnetic resonance imaging results from the DREaM study.

  2023cites this paper
• Cortical thickness, gray-white matter contrast, and intracortical myelin in first-episode schizophrenia patients treated with long-acting paliperidone palmitate versus oral antipsychotics.

  2023cites this paper
• Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal

  2023cites this paper
• Attitudes toward and patterns of medication use among people with serious mental illness: There’s more than meets the eye

  2023cites this paper
• Smartwatch digital phenotypes predict positive and negative symptom variation in a longitudinal monitoring study of patients with psychotic disorders

  2023cites this paper
• Switching from Monthly to Three-Monthly Long-Acting Injectable Paliperidone: A Survey on Subjective Satisfaction and Safety

  2023cites this paper
• Is preventing the second psychotic episode a disease-modifying strategy for schizophrenia?

  2023cites this paper
• Medication adherence among community-dwelling schizophrenia patients during the COVID-19 pandemic: A cross-sectional study

  2022cites this paper
• Efficacy and Safety of Second-generation Antipsychotics in Schizophrenia Pharmacotherapy: A Comparative Narrative Review

  2022cites this paper
• Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT.

  2022cites this paper
• The Disease Recovery Evaluation and Modification (DREaM) study: Effectiveness of paliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniform disorder.

  2022cites this paper
• Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study

  2021cites this paper
• Study on covert administration of medications practices among persons with severe mental illness: A cross-sectional study

  2021cites this paper
• The Willingness of Community Psychiatric Management Physicians to Preferentially Recommend Long-Acting Injections in Beijing

  2021cites this paper
• Relapse in patients with serious mental disorders during the COVID-19 outbreak: a retrospective chart review from a community mental health center

  2020cites this paper
• Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis

  2020cites this paper
• Working with People with Mental Health Difficulties to Improve Adherence to Medication

  2020cites this paper
• A randomized controlled trial of cognitive remediation and long-acting injectable risperidone after a first episode of schizophrenia: improving cognition and work/school functioning

  2020cites this paper
• Association between cortical volume and gray-white matter contrast with second generation antipsychotic medication exposure in first episode male schizophrenia patients.

  2020cites this paper
• A potential biomarker for treatment stratification in psychosis: evaluation of an [18F] FDOPA PET imaging approach

  2020cites this paper
• Terminology and assessment tools of psychosis: A systematic narrative review

  2019cites this paper
• Enhancing return to work or school after a first episode of schizophrenia: the UCLA RCT of Individual Placement and Support and Workplace Fundamentals Module training

  2019cites this paper
• Illness Insight and Antipsychotic Medication Adherence

  2019cites this paper
• The Association Between Medication Adherence and Disease Stability in Patients with Severe Mental Disorders and Area Variation: Community-Based Prospective Study in Southwest China

  2019cites this paper
• Early Signs Monitoring to Prevent Relapse in Psychosis and Promote Well-Being, Engagement, and Recovery: Protocol for a Feasibility Cluster Randomized Controlled Trial Harnessing Mobile Phone Technology Blended With Peer Support

  2019cites this paper
• Enhancing the Treatment of Patients With Schizophrenia Through Continuous Care.

  2019cites this paper
• Medication adherence in first episode psychosis: the role of pre‐onset subthreshold symptoms

  2019cites this paper
• Development and content validation of measures assessing adherence barriers and behaviors for use in clinical care.

  2019cites this paper
• The clinician–patient working alliance: is it a significant predictor of psychiatric medication adherence in a sample of recently released parolees?

  2018cites this paper
• A quantitative systems pharmacology study on optimal scenarios for switching to paliperidone palmitate once-monthly.

  2018cites this paper
• Retrospective Accounts of the Process of Using and Discontinuing Psychiatric Medication

  2018cites this paper
• Does knowledge of patient non-compliance change prescribing behavior in the real world? A claims-based analysis of patients with serious mental illness

  2018cites this paper
• Family burden predicts functional outcome in the early course of schizophrenia beyond psychiatric symptoms and baseline functioning.

  2018cites this paper
• Access to credible information on schizophrenia patients’ medication adherence by prescribers can change their treatment strategies: evidence from an online survey of providers

  2017cites this paper
• 11 Psychotic Disorders in Emergency Departments

  2017cites this paper
• Antipsychotic treatment, psychoeducation & regular follow up as a public health strategy for schizophrenia: Results from a prospective study

  2017cites this paper
• Five-fold increased risk of relapse following breaks in antipsychotic treatment of first episode psychosis.

  2017cites this paper
• Schizophrenie – hohe Adhärenz von Beginn an

  2017cites this paper
• Perceptions and knowledge of antipsychotics among mental health professionals and patients

  2017cites this paper
• Abnormal Trajectory of Intracortical Myelination in Schizophrenia Implicates White Matter in Disease Pathophysiology and the Therapeutic Mechanism of Action of Antipsychotics.

  2017cites this paper
• Applications of temporal kernel canonical correlation analysis in adherence studies

  2017cites this paper
• Community Health Workers: a Resource to Support Antipsychotic Medication Adherence

  2017cites this paper
• Bei Schizophrenie von Anfang an auf hohe Adhärenz setzen

  2017cites this paper
• The cost of adherence mismeasurement in serious mental illness: a claims-based analysis.

  2017cites this paper
• Diagnosis Conceptual Issues and Controversies

  2016cites this paper
• Recommendations for the optimal care of patients with recent‐onset psychosis in the Asia‐Pacific region

  2016influential citation
• Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia

  2016cites this paper
• Comparison of intensive case management for psychotic and nonpsychotic patients.

  2016cites this paper
• Medication adherence in patients with schizophrenia

  2016cites this paper
• The RAISE Connection Program: Psychopharmacological Treatment of People With a First Episode of Schizophrenia.

  2016cites this paper
• Enhancing Cognitive Training Through Aerobic Exercise After a First Schizophrenia Episode: Theoretical Conception and Pilot Study.

  2016cites this paper
• Recovery from psychosis: physical health, antipsychotic medication and the daily dilemmas for mental health nurses.

  2015cites this paper
• Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent‐onset versus more chronic schizophrenia and a history of criminal justice system involvement

  2015cites this paper
• Do patterns of mental healthcare predict treatment failure in young people with schizophrenia? Evidence from an Italian population-based cohort study

  2015cites this paper
• Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?

  2015cites this paper
• Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia

  2015cites this paper
• Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later.

  2015cites this paper
• Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.

  2015cites this paper
• Development and application of an aggregate adherence metric derived from population pharmacokinetics to inform clinical trial enrichment

  2015cites this paper
• Is Monitoring of Plasma Antipsychotic Levels Useful

  2015cites this paper
• A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders.

  2015cites this paper
• The relationship between second-generation antipsychotic medication adherence and negative symptoms in first-episode schizophrenia

  2015cites this paper
• Are there clinically useful predictors and early warning signs for pending relapse?

  2014cites this paper
• Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial.

  2014cites this paper
• Long-acting injectable antipsychotics: shall the last be first?

  2014cites this paper
• Consensus statements on adherence issues in schizophrenia for Hong Kong.

  2014cites this paper
• Association of violence with emergence of persecutory delusions in untreated schizophrenia.

  2014cites this paper
• A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea

  2014cites this paper
• The impact of second-generation antipsychotic adherence on positive and negative symptoms in recent-onset schizophrenia.

  2014cites this paper
• Experiencing antipsychotic discontinuation: results from a survey of Australian consumers.

  2014cites this paper
• Cognitive remediation in schizophrenia: efficacy and effectiveness in patients with early versus long‐term course of illness

  2014cites this paper
• Medication Adherence, Knowledge About Psychosis, and Insight Among Patients With a Schizophrenia-Spectrum Disorder

  2014cites this paper
• Long-Term Pharmacological Management of Schizophrenia

  2014cites this paper
• Certifiable Disability in First Episode Schizophrenia: The Role of Adherence to Antipsychotic Treatment

  2014cites this paper
• Poor Adherence to Antipsychotic Medication in People with Schizophrenia: Diffusion, Consequences and Contributing Factors

  2014influential citation
• COGNITIVE THERAPY FOR PEOPLE WITH SCHIZOPHRENIA SPECTRUM DISORDERS NOT TAKING ANTIPSYCHOTIC MEDICATION: A RANDOMISED CONTROLLED TRIAL

  2014cites this paper
• A Qualitative Study of Experiences with and Perceptions regarding Long-Acting Injectable Antipsychotics: Part II—Physician Perspectives

  2013cites this paper
• A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives.

  2013cites this paper
• Alternative Delivery Systems for Agents to Treat Acute Agitation: Progress to Date

  2013cites this paper
• Impact of Early Nonadherence to Oral Antipsychotics on Clinical and Economic Outcomes Among Patients with Schizophrenia

  2013cites this paper
• Assertive community treatment in veterans affairs settings: impact on adherence to antipsychotic medication.

  2013cites this paper
• Long-Acting Injectable Antipsychotics: Recommendations for Clinicians

  2013cites this paper
• Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year.

  2013cites this paper
• An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis.

  2013cites this paper
• Chapter 1 Issues in Diagnosis Conceptual Issues and Controversies

  2013cites this paper
• Adherence and long-acting injectable antipsychotics in schizophrenia: an update -

  2012cites this paper
• Strategies for optimizing medication adherence in schizophrenia

  2012cites this paper
• Schizophrenia Spectrum Conditions

  2012cites this paper
• Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments.

  2012cites this paper
• Costs and Use of Oral Anti-cancer Medications among Senior Medicare Part D Beneficiaries

  2012cites this paper
• Assessing Adherence to Antipsychotic Medications

  2012cites this paper
• Rethinking the role of long-acting atypical antipsychotics in the community setting

  2012cites this paper
• Optimizing Outcomes in Schizophrenia: Long-acting Depots and Long-term Treatment

  2012cites this paper
• Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia.

  2012influential citation
• Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia

  2012cites this paper